1. Home
  2. Live Updates
  3. India subject expert committee

Live Breaking News & Updates on India subject expert committee

Stay informed with the latest breaking news from India subject expert committee on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in India subject expert committee and stay connected to the pulse of your community

Nearly 100 Deaths Caused by COVID-19 Vaccines: Government Data From Major Countries (Part 1)

While potentially fatal blood clots and heart inflammation have been acknowledged as rare side effects of the COVID-19 ...

United-states , Canada , United-kingdom , Australia , New-zealand , Japan , India , Bangladesh , Ireland , Finland , Austria , Denmark

Corbevax COVID vaccine is safe, offers high antibody levels: NTAGI chief

The remarks came after DCGI recommended Emergency Use Authorization to Biological E's vaccine, Corbevax

India , New-delhi , Delhi , National-technical-advisory-group , India-subject-expert-committee , Serum-institute , Drugs-controller-general , Subject-expert-committee , Emergency-use-authorization , Hyderabad-based-pharmaceutical , Corbevax

Corbevax COVID vaccine is safe, offers high antibody levels: NTAGI chief

The remarks came after DCGI recommended Emergency Use Authorization to Biological E's vaccine, Corbevax

India , New-delhi , Delhi , National-technical-advisory-group , India-subject-expert-committee , Serum-institute , Drugs-controller-general , Subject-expert-committee , Emergency-use-authorization , Hyderabad-based-pharmaceutical , Corbevax

Corbevax COVID vaccine is safe, offers high antibody levels: NTAGI chief

The remarks came after DCGI recommended Emergency Use Authorization to Biological E's vaccine, Corbevax

India , New-delhi , Delhi , National-technical-advisory-group , India-subject-expert-committee , Serum-institute , Drugs-controller-general , Subject-expert-committee , Emergency-use-authorization , Hyderabad-based-pharmaceutical , Corbevax

NTAGI chief says Corbevax Covid vaccine is safe, provides high antibody levels

NTAGI chief says Corbevax Covid vaccine is safe, provides high antibody levels - The country’s central drug authority is soon expected to give final approval to Corbevax, which is a two-dose vaccine.

India , National-technical-advisory-group , India-subject-expert-committee , Serum-institute , Drugs-controller-general , Subject-expert-committee , Emergency-use-authorization , Hyderabad-based-pharmaceutical , Covid-19 , Ovid-vaccine , Orbevax

Omicron Threat: Its transmissibility, vaccine escape potential

Vaccine effectiveness against symptomatic Omicron infection is 0-20 per cent after two vaccine doses, and between 55 per cent and 80 per cent after booster shots.

Manipur , Uttar-pradesh , India , United-states , United-kingdom , Israel , South-africa , France , London , City-of , Alex-sigal , Maria-van-kerkhove

Is Omicron more transmissible than Delta strain?

The column discusses the issues of symptoms of Omicron infections, its transmissibility, severity and the status of booster doses in India.

South-africa , Manipur , Uttar-pradesh , India , United-states , United-kingdom , Kerala , Israel , Alex-sigal , Genome-consortium , India-subject-expert-committee , Dr-david-ho-of-columbia-university

Is Omicron more transmissible than Delta strain?

The column discusses the issues of symptoms of Omicron infections, its transmissibility, severity and the status of booster doses in India.

South-africa , Manipur , Uttar-pradesh , India , United-states , United-kingdom , Kerala , Israel , Alex-sigal , Genome-consortium , India-subject-expert-committee , Dr-david-ho-of-columbia-university

Here's Why Ocugen Stock Skyrocketed 64.9% in October

The biotech stock is now up a staggering 756% year to date.

India , Bharat , India-subject-expert-committee , World-health-organization , Drug-administration , Bharat-biotech , Emergency-use-authorization , Subject-expert , Emergency-use-listing , Subject-expert-committee ,

Here's Why Ocugen Stock Skyrocketed 64.9% in October

The biotech stock is now up a staggering 756% year to date.

India , Bharat , India-subject-expert-committee , World-health-organization , Drug-administration , Bharat-biotech , Emergency-use-authorization , Subject-expert , Emergency-use-listing , Subject-expert-committee ,